AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Lenny Dang et al.|Cancer Discovery|2017Cited by 457